Table 1.

Summary of drug pairs overlapping for highest efficacy and synergy

Average efficacyAverage synergy
Drug 1Drug 2Mutant BRAFMutant RASwtBRAF/wtRASMutant BRAFMutant RASwtBRAF/wtRAS
Mutant BRAF-selective
BosutinibMK-22060.850.530.540.370.110.15
LapatinibDovitinib0.840.510.670.310.040.16
LapatinibMK-22060.810.320.510.380.090.19
LapatinibPHA 6657520.880.430.600.430.140.23
LapatinibTozasertib0.860.460.670.380.030.21
MK-2206PD1730740.840.510.630.310.100.14
ObatoclaxPD1730740.840.670.680.450.250.24
PD173074Vorinostat0.840.480.570.300.050.11
Mutant RAS-selective
SimvastatinBMS-5369240.580.840.650.090.120.03
SimvastatinCIP-13740.600.830.600.110.130.05
SimvastatinTemozolomide0.570.830.580.140.060.12
SimvastatinVinblastine0.560.820.640.080.090.05
Simvastatin17-DMAG0.590.810.660.060.060.03
SimvastatinJK 1840.600.810.630.120.080.09
SimvastatinPX 120.620.810.590.160.040.06
SimvastatinFlavopiridol0.600.800.640.210.180.23
Nongenotype-Specific
StatticFAK Inhibitor 140.960.950.940.440.470.52
ObatoclaxFlavopiridol0.950.890.880.500.320.38
VorinostatFlavopiridol0.830.790.880.420.280.43

NOTE: Drug combinations overlapping for highest average synergy and effectiveness (>GI80) with respect to a specific genotypic group (at least 15% higher growth inhibition than other two groups), or those without genotype selectivity. Average efficacy (percent as decimal) and average synergy values (percent as decimal over predicted Bliss additivity) of the 9 concentration combinations are shown for each drug pair. Drug pairs chosen for confirmation of cytotoxicity are bold-faced.